Jefferies (NYSE:JEF) analyst Michael Yee maintained a Buy rating on Akero Therapeutics (NASDAQ:AKRO) Inc on Tuesday, setting a price target of $48, which is approximately 51.42% above the present share price of $31.7.
Yee expects Akero Therapeutics Inc to post earnings per share (EPS) of -$0.63 for the first quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Akero Therapeutics, with an average price target of $61.
The analysts price targets range from a high of $81 to a low of $48.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $0 and a net profit of -$21.54 million. The company's market cap is $1.1 billion.
According to TipRanks.com, Jefferies analyst Michael Yee is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 6.7% and a 48.80% success rate.
Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.